Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353047 | 1.00 | ACACB (0.39) | ACACBACACANR1H4CYP1A1CYP1B1 | |
| SCHEMBL4710036 | 0.94 | ACACB (0.33) | ACACBACACA | |
| SCHEMBL4822853 | 0.84 | PDK2 (0.33) | — | |
| SCHEMBL4708596 | 0.82 | ACACA (0.36) | ACACBACACA | |
| SCHEMBL4276308 | 0.81 | ACACB (0.43) | ACACBACACANR1H4CYP1A1CYP1B1 | |
| SCHEMBL4708996 | 0.80 | ACACA (0.35) | ACACBACACA | |
| SCHEMBL4759663 | 0.79 | TTK (0.37) | ACACBACACA | |
| SCHEMBL502156 | 0.79 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL1570410 | 0.78 | DYRK1A (0.36) | — | |
| SCHEMBL1444711 | 0.78 | ACACB (0.51) | ACACBACACACYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593155-B2 | Oxyntomodulin analogs | MERCK SHARP & DOHME CORP. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9540364-B2 | Benzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150307580-A1 | OXYNTOMODULIN ANALOGS | MERCK SHARP & DOHME (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2838906-A1 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS | Kaneq Pharma Inc. (CA) | 2015-02-25 | — | — | EP | disclosed |
| EP-2680851-A2 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013155600-A1 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS | KANEQ PHARMA (CA) | 2013-10-24 | — | — | WO | disclosed |
| WO-2012118945-A2 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2480082-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2473047-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011037793-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011028455-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307580-A1 | OXYNTOMODULIN ANALOGS | GLP1R, GCGR, GIPR | ACACB 2712/4885ACACA 1982/4885NR1H4 791/4885 |
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | PRKAG2, AK2, PRKAB2 | ACACB 20/4885ACACA 52/4885NR1H4 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.